

Global Inhalation CDMO Market Analysis and Forecast 2025-2031

<https://marketpublishers.com/r/GE81B00E22A2EN.html>

Date: February 2025

Pages: 204

Price: US\$ 4,950.00 (Single User License)

ID: GE81B00E22A2EN

Abstracts

Summary

According to APO Research, The global Inhalation CDMO market is projected to grow from US\$ million in 2025 to US\$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Inhalation CDMO is estimated to increase from \$ million in 2025 to reach \$ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Inhalation CDMO is estimated to increase from \$ million in 2025 to reach \$ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Inhalation CDMO is estimated to increase from \$ million in 2025 to reach \$ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Inhalation CDMO is estimated to increase from \$ million in 2025 to reach \$ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Inhalation CDMO include Aptar Pharma, Bend Bioscience, Bespak, Catalent, CritiTech, Enteris Biopharma, Experic, HCmed and Hovione, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Inhalation CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Inhalation CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Inhalation CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Inhalation CDMO revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Inhalation CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Inhalation CDMO revenue, projected growth trends, production technology, application and end-user industry.

Inhalation CDMO Segment by Company

Aptar Pharma

Bend Bioscience

Bespak

Catalent

CritiTech

Enteris Biopharma

Experic

HCmed

Hovione

Iconovo

Kindeva

Lonza

Particle Sciences

Proveris

Recipharm

Renejix

Ritedose

Vectura

Sanner

Inhalation CDMO Segment by Type

Soft Mist Inhalers (SMIs)

Dry Powder Inhalers (DPIs)

Metered Dose Inhalers (MDIs)

Others

Inhalation CDMO Segment by Application

Commercial

Academic Research

Others

Inhalation CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Turkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inhalation CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inhalation CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest

developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inhalation CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Inhalation CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Inhalation CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Inhalation CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

Contents

1 MARKET OVERVIEW

- 1.1 Product Definition
- 1.2 Inhalation CDMO Market by Type
 - 1.2.1 Global Inhalation CDMO Market Size by Type, 2020 VS 2024 VS 2031
 - 1.2.2 Soft Mist Inhalers (SMIs)
 - 1.2.3 Dry Powder Inhalers (DPIs)
 - 1.2.4 Metered Dose Inhalers (MDIs)
 - 1.2.5 Others
- 1.3 Inhalation CDMO Market by Application
 - 1.3.1 Global Inhalation CDMO Market Size by Application, 2020 VS 2024 VS 2031
 - 1.3.2 Commercial
 - 1.3.3 Academic Research
 - 1.3.4 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives

2 INHALATION CDMO MARKET DYNAMICS

- 2.1 Inhalation CDMO Industry Trends
- 2.2 Inhalation CDMO Industry Drivers
- 2.3 Inhalation CDMO Industry Opportunities and Challenges
- 2.4 Inhalation CDMO Industry Restraints

3 GLOBAL GROWTH PERSPECTIVE

- 3.1 Global Inhalation CDMO Market Perspective (2020-2031)
- 3.2 Global Inhalation CDMO Growth Trends by Region
 - 3.2.1 Global Inhalation CDMO Market Size by Region: 2020 VS 2024 VS 2031
 - 3.2.2 Global Inhalation CDMO Market Size by Region (2020-2025)
 - 3.2.3 Global Inhalation CDMO Market Size by Region (2026-2031)

4 COMPETITIVE LANDSCAPE BY PLAYERS

- 4.1 Global Inhalation CDMO Revenue by Players
 - 4.1.1 Global Inhalation CDMO Revenue by Players (2020-2025)
 - 4.1.2 Global Inhalation CDMO Revenue Market Share by Players (2020-2025)

- 4.1.3 Global Inhalation CDMO Players Revenue Share Top 10 and Top 5 in 2024
- 4.2 Global Inhalation CDMO Key Players Ranking, 2023 VS 2024 VS 2025
- 4.3 Global Inhalation CDMO Key Players Headquarters & Area Served
- 4.4 Global Inhalation CDMO Players, Product Type & Application
- 4.5 Global Inhalation CDMO Players Establishment Date
- 4.6 Market Competitive Analysis
 - 4.6.1 Global Inhalation CDMO Market CR5 and HHI
 - 4.6.3 2024 Inhalation CDMO Tier 1, Tier 2, and Tier

5 INHALATION CDMO MARKET SIZE BY TYPE

- 5.1 Global Inhalation CDMO Revenue by Type (2020 VS 2024 VS 2031)
- 5.2 Global Inhalation CDMO Revenue by Type (2020-2031)
- 5.3 Global Inhalation CDMO Revenue Market Share by Type (2020-2031)

6 INHALATION CDMO MARKET SIZE BY APPLICATION

- 6.1 Global Inhalation CDMO Revenue by Application (2020 VS 2024 VS 2031)
- 6.2 Global Inhalation CDMO Revenue by Application (2020-2031)
- 6.3 Global Inhalation CDMO Revenue Market Share by Application (2020-2031)

7 COMPANY PROFILES

- 7.1 Aptar Pharma
 - 7.1.1 Aptar Pharma Company Information
 - 7.1.2 Aptar Pharma Business Overview
 - 7.1.3 Aptar Pharma Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.1.4 Aptar Pharma Inhalation CDMO Product Portfolio
 - 7.1.5 Aptar Pharma Recent Developments
- 7.2 Bend Bioscience
 - 7.2.1 Bend Bioscience Company Information
 - 7.2.2 Bend Bioscience Business Overview
 - 7.2.3 Bend Bioscience Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.2.4 Bend Bioscience Inhalation CDMO Product Portfolio
 - 7.2.5 Bend Bioscience Recent Developments
- 7.3 Bepak
 - 7.3.1 Bepak Company Information
 - 7.3.2 Bepak Business Overview
 - 7.3.3 Bepak Inhalation CDMO Revenue and Gross Margin (2020-2025)

- 7.3.4 Bespak Inhalation CDMO Product Portfolio
- 7.3.5 Bespak Recent Developments
- 7.4 Catalent
 - 7.4.1 Catalent Company Information
 - 7.4.2 Catalent Business Overview
 - 7.4.3 Catalent Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.4.4 Catalent Inhalation CDMO Product Portfolio
 - 7.4.5 Catalent Recent Developments
- 7.5 CritiTech
 - 7.5.1 CritiTech Company Information
 - 7.5.2 CritiTech Business Overview
 - 7.5.3 CritiTech Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.5.4 CritiTech Inhalation CDMO Product Portfolio
 - 7.5.5 CritiTech Recent Developments
- 7.6 Enteris Biopharma
 - 7.6.1 Enteris Biopharma Company Information
 - 7.6.2 Enteris Biopharma Business Overview
 - 7.6.3 Enteris Biopharma Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.6.4 Enteris Biopharma Inhalation CDMO Product Portfolio
 - 7.6.5 Enteris Biopharma Recent Developments
- 7.7 Experic
 - 7.7.1 Experic Company Information
 - 7.7.2 Experic Business Overview
 - 7.7.3 Experic Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.7.4 Experic Inhalation CDMO Product Portfolio
 - 7.7.5 Experic Recent Developments
- 7.8 HCmed
 - 7.8.1 HCmed Company Information
 - 7.8.2 HCmed Business Overview
 - 7.8.3 HCmed Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.8.4 HCmed Inhalation CDMO Product Portfolio
 - 7.8.5 HCmed Recent Developments
- 7.9 Hovione
 - 7.9.1 Hovione Company Information
 - 7.9.2 Hovione Business Overview
 - 7.9.3 Hovione Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.9.4 Hovione Inhalation CDMO Product Portfolio
 - 7.9.5 Hovione Recent Developments
- 7.10 Iconovo

- 7.10.1 Iconovo Company Information
- 7.10.2 Iconovo Business Overview
- 7.10.3 Iconovo Inhalation CDMO Revenue and Gross Margin (2020-2025)
- 7.10.4 Iconovo Inhalation CDMO Product Portfolio
- 7.10.5 Iconovo Recent Developments
- 7.11 Kindeva
 - 7.11.1 Kindeva Company Information
 - 7.11.2 Kindeva Business Overview
 - 7.11.3 Kindeva Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.11.4 Kindeva Inhalation CDMO Product Portfolio
 - 7.11.5 Kindeva Recent Developments
- 7.12 Lonza
 - 7.12.1 Lonza Company Information
 - 7.12.2 Lonza Business Overview
 - 7.12.3 Lonza Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.12.4 Lonza Inhalation CDMO Product Portfolio
 - 7.12.5 Lonza Recent Developments
- 7.13 Particle Sciences
 - 7.13.1 Particle Sciences Company Information
 - 7.13.2 Particle Sciences Business Overview
 - 7.13.3 Particle Sciences Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.13.4 Particle Sciences Inhalation CDMO Product Portfolio
 - 7.13.5 Particle Sciences Recent Developments
- 7.14 Proveris
 - 7.14.1 Proveris Company Information
 - 7.14.2 Proveris Business Overview
 - 7.14.3 Proveris Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.14.4 Proveris Inhalation CDMO Product Portfolio
 - 7.14.5 Proveris Recent Developments
- 7.15 Recipharm
 - 7.15.1 Recipharm Company Information
 - 7.15.2 Recipharm Business Overview
 - 7.15.3 Recipharm Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.15.4 Recipharm Inhalation CDMO Product Portfolio
 - 7.15.5 Recipharm Recent Developments
- 7.16 Renejix
 - 7.16.1 Renejix Company Information
 - 7.16.2 Renejix Business Overview
 - 7.16.3 Renejix Inhalation CDMO Revenue and Gross Margin (2020-2025)

- 7.16.4 Renejix Inhalation CDMO Product Portfolio
- 7.16.5 Renejix Recent Developments
- 7.17 Ritedose
 - 7.17.1 Ritedose Comapny Information
 - 7.17.2 Ritedose Business Overview
 - 7.17.3 Ritedose Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.17.4 Ritedose Inhalation CDMO Product Portfolio
 - 7.17.5 Ritedose Recent Developments
- 7.18 Vectura
 - 7.18.1 Vectura Comapny Information
 - 7.18.2 Vectura Business Overview
 - 7.18.3 Vectura Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.18.4 Vectura Inhalation CDMO Product Portfolio
 - 7.18.5 Vectura Recent Developments
- 7.19 Sanner
 - 7.19.1 Sanner Comapny Information
 - 7.19.2 Sanner Business Overview
 - 7.19.3 Sanner Inhalation CDMO Revenue and Gross Margin (2020-2025)
 - 7.19.4 Sanner Inhalation CDMO Product Portfolio
 - 7.19.5 Sanner Recent Developments

8 NORTH AMERICA

- 8.1 North America Inhalation CDMO Revenue (2020-2031)
- 8.2 North America Inhalation CDMO Revenue by Type (2020-2031)
 - 8.2.1 North America Inhalation CDMO Revenue by Type (2020-2025)
 - 8.2.2 North America Inhalation CDMO Revenue by Type (2026-2031)
- 8.3 North America Inhalation CDMO Revenue Share by Type (2020-2031)
- 8.4 North America Inhalation CDMO Revenue by Application (2020-2031)
 - 8.4.1 North America Inhalation CDMO Revenue by Application (2020-2025)
 - 8.4.2 North America Inhalation CDMO Revenue by Application (2026-2031)
- 8.5 North America Inhalation CDMO Revenue Share by Application (2020-2031)
- 8.6 North America Inhalation CDMO Revenue by Country
 - 8.6.1 North America Inhalation CDMO Revenue by Country (2020 VS 2024 VS 2031)
 - 8.6.2 North America Inhalation CDMO Revenue by Country (2020-2025)
 - 8.6.3 North America Inhalation CDMO Revenue by Country (2026-2031)
 - 8.6.4 United States
 - 8.6.5 Canada
 - 8.6.6 Mexico

9 EUROPE

- 9.1 Europe Inhalation CDMO Revenue (2020-2031)
- 9.2 Europe Inhalation CDMO Revenue by Type (2020-2031)
 - 9.2.1 Europe Inhalation CDMO Revenue by Type (2020-2025)
 - 9.2.2 Europe Inhalation CDMO Revenue by Type (2026-2031)
- 9.3 Europe Inhalation CDMO Revenue Share by Type (2020-2031)
- 9.4 Europe Inhalation CDMO Revenue by Application (2020-2031)
 - 9.4.1 Europe Inhalation CDMO Revenue by Application (2020-2025)
 - 9.4.2 Europe Inhalation CDMO Revenue by Application (2026-2031)
- 9.5 Europe Inhalation CDMO Revenue Share by Application (2020-2031)
- 9.6 Europe Inhalation CDMO Revenue by Country
 - 9.6.1 Europe Inhalation CDMO Revenue by Country (2020 VS 2024 VS 2031)
 - 9.6.2 Europe Inhalation CDMO Revenue by Country (2020-2025)
 - 9.6.3 Europe Inhalation CDMO Revenue by Country (2026-2031)
 - 9.6.4 Germany
 - 9.6.5 France
 - 9.6.6 U.K.
 - 9.6.7 Italy
 - 9.6.8 Russia
 - 9.6.9 Spain
 - 9.6.10 Netherlands
 - 9.6.11 Switzerland
 - 9.6.12 Sweden
 - 9.6.13 Poland

10 CHINA

- 10.1 China Inhalation CDMO Revenue (2020-2031)
- 10.2 China Inhalation CDMO Revenue by Type (2020-2031)
 - 10.2.1 China Inhalation CDMO Revenue by Type (2020-2025)
 - 10.2.2 China Inhalation CDMO Revenue by Type (2026-2031)
- 10.3 China Inhalation CDMO Revenue Share by Type (2020-2031)
- 10.4 China Inhalation CDMO Revenue by Application (2020-2031)
 - 10.4.1 China Inhalation CDMO Revenue by Application (2020-2025)
 - 10.4.2 China Inhalation CDMO Revenue by Application (2026-2031)
- 10.5 China Inhalation CDMO Revenue Share by Application (2020-2031)

11 ASIA (EXCLUDING CHINA)

- 11.1 Asia Inhalation CDMO Revenue (2020-2031)
- 11.2 Asia Inhalation CDMO Revenue by Type (2020-2031)
 - 11.2.1 Asia Inhalation CDMO Revenue by Type (2020-2025)
 - 11.2.2 Asia Inhalation CDMO Revenue by Type (2026-2031)
- 11.3 Asia Inhalation CDMO Revenue Share by Type (2020-2031)
- 11.4 Asia Inhalation CDMO Revenue by Application (2020-2031)
 - 11.4.1 Asia Inhalation CDMO Revenue by Application (2020-2025)
 - 11.4.2 Asia Inhalation CDMO Revenue by Application (2026-2031)
- 11.5 Asia Inhalation CDMO Revenue Share by Application (2020-2031)
- 11.6 Asia Inhalation CDMO Revenue by Country
 - 11.6.1 Asia Inhalation CDMO Revenue by Country (2020 VS 2024 VS 2031)
 - 11.6.2 Asia Inhalation CDMO Revenue by Country (2020-2025)
 - 11.6.3 Asia Inhalation CDMO Revenue by Country (2026-2031)
 - 11.6.4 Japan
 - 11.6.5 South Korea
 - 11.6.6 India
 - 11.6.7 Australia
 - 11.6.8 Taiwan
 - 11.6.9 Southeast Asia

12 SOUTH AMERICA, MIDDLE EAST AND AFRICA

- 12.1 SAMEA Inhalation CDMO Revenue (2020-2031)
- 12.2 SAMEA Inhalation CDMO Revenue by Type (2020-2031)
 - 12.2.1 SAMEA Inhalation CDMO Revenue by Type (2020-2025)
 - 12.2.2 SAMEA Inhalation CDMO Revenue by Type (2026-2031)
- 12.3 SAMEA Inhalation CDMO Revenue Share by Type (2020-2031)
- 12.4 SAMEA Inhalation CDMO Revenue by Application (2020-2031)
 - 12.4.1 SAMEA Inhalation CDMO Revenue by Application (2020-2025)
 - 12.4.2 SAMEA Inhalation CDMO Revenue by Application (2026-2031)
- 12.5 SAMEA Inhalation CDMO Revenue Share by Application (2020-2031)
- 12.6 SAMEA Inhalation CDMO Revenue by Country
 - 12.6.1 SAMEA Inhalation CDMO Revenue by Country (2020 VS 2024 VS 2031)
 - 12.6.2 SAMEA Inhalation CDMO Revenue by Country (2020-2025)
 - 12.6.3 SAMEA Inhalation CDMO Revenue by Country (2026-2031)
 - 12.6.4 Brazil
 - 12.6.5 Argentina

- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt

13 CONCLUDING INSIGHTS

14 APPENDIX

- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
 - 14.5.1 Secondary Sources
 - 14.5.2 Primary Sources
- 14.6 Disclaimer

I would like to order

Product name: Global Inhalation CDMO Market Analysis and Forecast 2025-2031

Product link: <https://marketpublishers.com/r/GE81B00E22A2EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE81B00E22A2EN.html>